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ABSTRACT
Breast cancer is one of the most frequent cancers among women worldwide and
holds the second place in cancer-related death. Mammography is the most commonly used
screening technique, however, the dense nature of some breasts makes the analysis of
mammograms challenging for radiologists. The 2D Wavelet Transform Modulus Maxima
(WTMM) is one mathematical approach that is used to for the analysis of mammograms. In

2014, a team from the CompuMAINE Lab characterized differences between benign
microcalcification clusters (MC) from malignant MC by calculating their fractal
dimension, D, with the aid of the 2D WTMM method. In a different implementation of the
2D WTMM method, this same team did research in 2017 where they quantified tissue
disruption in breast tissue microenvironment using the Hurst exponent, H. The goal of this
study was to further explore the potential relationship between the fractality of MC clusters
and tissue disruption in the microenvironment surrounding these clusters. Statistical
relationships are explored between the fractal dimension, D, of MC clusters and the Hurst
exponent, H measuring tissue disruption. A “2D fractal dimension vs. Hurst exponent plot”
was graphed to show this relationship used to distinguish between benign and malignant
cases. In the graph, a quadrilateral region extending horizontally from Hurst value of
(0.2,0.8) centered at 0.5 and stretching vertically from fractal dimension value of (1.2,1.8)
centered 1.5 was identified. Analysis of this region has showed that the 60% of the
malignant cases and 21% benign cases are found inside the quadrilateral for CC view and
68% of the malignant cases and 12% of benign cases are found inside the region for MLO
view. As a conclusion, based on the outcomes of this study one can hypothesize that with
further analyses, loss of tissue homeostasis describing the state of the microenvironment of a

breast tissue and the fractal nature of MC clusters have a quantifiable relationship to distinguish
benign cases from malignant cases in mammogram analysis.
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CHAPTER 1: INTRODUCTION
Breast cancer is one of the most common diseases around the world that affects
many families' lives. If caught early, breast cancer can be treated before further
complications occur. Most of the current existing breast imaging techniques include
magnetic resonance imaging (MRI), ultrasound, and mammography (low energy x-rays).
Ultrasound and mammography imaging are the two most common techniques used to
screen breast cancer. MRI is a more sensitive method of breast screening and unlike the
other two methods, it is virtually uninfluenced by breast density, but it is expensive.1–4
Computer-aided diagnostics (CAD) are systems that were invented to assist doctors with
the interpretation of medical images (like breast images) and have been in application for
several years. Since these CAD techniques have been approved by the FDA, the rate at
which malignant tumors or suspicious cancer zone identification such as microcalcification
detection has shown a potential increase by approximately 20%.5 This statistics is based on
the recall rates for mammogram analysis with and without CAD by experienced
radiologists. Most developed countries like the US use these technologies to assist
radiologists in interpreting mammography images, which eases their job and also gives a
better insight into suspicious (cancerous) regions.5 However, this widely used technology
has unfortunately been associated with false diagnostics. Improving the efficiency of
analyzing images using these CAD techniques is crucial in minimizing the morbidity and
mortality rate of cancer around the world.
Some of the factors that could lower the sensitivity of mammography include
technical and interpretative errors, rapid tumor growth and its patterns, and extensive
mammographic breast density.6 The breast tissue microenvironment plays an important
1

role in the growth of malignant or benign tumors. Developing a quantitative support for a
mathematical interpretation of the breast microenvironment could help in understanding
the different patterns and progression of tumor 2growth. The concept of fractal geometry
is one mathematical approach that could be applied to solve this difficulty in breast image
interpretation. Fractal geometry is a tool that is used to study objects with irregular
geometry (non-integer values of dimension D), rather than the regular 1-D, 2-D, or 3-D
geometries mostly referred as Euclidean objects (integer values of dimension D).7 The
fractal dimension, D, refers to the exponent in the power-law relationship between the
number of balls required to cover a set, N, and the radius of the balls, r, i.e. N ~ (1/r)D as
shown in Figure 1. Previous mathematical studies have shown that benign tumors have a
Euclidean geometry form of growth whereas malignant tumors follow the fractal geometry
form of growth.7,8 The fractal growth nature of the malignant tumors can be used to create
a fractal-based background model of breast tissue in order to find calcification clusters.9–11

Figure 1: Different radii balls covering the perimeter of Koch’s island.
Adopted from Ref. [12]
Breasts are organs with a very dense tissue composition with mostly fatty tissue
and some fibrous and glandular tissues. Although the source is not clearly known, the
lactation ducts in the breast can start having calcium deposits that cluster in two main,
2

different ways. These calcification clusters are divided into macrocalcification clusters
(mainly associated with benign tissues) and microcalcification (MC) clusters (mainly
associated with malignant tissues). Calcification clusters are major and very important
when looking at a mammography image, (mammograms) as they are suspected to be
regions of malignant tumors. Previous research has been conducted on the geometry of
microcalcifications by the CompuMAINE Lab, at the University of Maine, by studying the
fractal dimension of MC clusters. The outcome of the study is that benign breast lesions
were identified to have a fractal dimension, D of 1 or 2 (Euclidean dimension) but
malignant breast lesions have D closer to 1.5 (i.e. a non-integer, fractal dimension).7 A
different research conducted by this same team studied the architecture of breast
microenvironment by using the Hurst exponent, H, as a quantifying index.13 In that study
they showed evidence that tissue disruption and loss of homeostasis in breast tissue
microenvironment and breast bilateral asymmetry can be quantitatively assessed from
mammography using a wavelet analysis of the whole breast. The outcome from that study
has shown a potential for the development of a metric that can study the biophysics of loss
of tissue homeostasis and breast tissue disruption that enhances the possibility for early
identification of potential danger zones.
The development of a more reliable and valuable quantitative assessment
methodology based on fractal geometry could assist in mammography interpretation,
leading to an improved cancer detection accuracy. In this project the mathematical
calculations for H and D from mammograms previously analyzed with the aid of the 2D
Wavelet-Transform Modulus Maxima (WTMM) method were made available by the
CompuMAINE Lab. The goal of this project is to explore potential correlations between
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the fractality of the breast tumors (MC clusters) and the state of tissue homeostasis of the
microenvironment surrounding these tumors. To do so, we investigated statistical
relationships between the fractal dimension of MC clusters (D) and microenvironment
tissue disruption as measured by the Hurst exponent, H. Based on the outcomes from the
2014 and the 2017 studies, it is expected that this statistical analysis is going to show a
significant relationship between the Hurst exponent and the fractal dimension.
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CHAPTER 2: BREAST ANATOMY AND CALCIFICATION
2.1 Normal Anatomy and Physiology
The breast is located on the upper ventral region of the torso in primates. Breasts
start to develop in the first five weeks of the human fetus, as the mammary ridge starts to
develop on either side from the axilla to the groin. The axilla contains the vessels and
nerves of the upper extremity. Breasts are composed of different tissue layers mainly of
glandular (secretory) tissues and adipose (fatty) tissues surrounded by a loose framework
of fibrous connective tissues called Cooper’s ligaments. The human breast reaches its full
functional capability when it develops enough glandulars for lactation (milk secretion)
which also acts as a means of communication between the baby and the mother.14 The
mammary glands of the breast always find a way to secrete or continuously supply calcium
in order to concentrate the milk with the needed amount of calcium. However, a large
amount of calcium is toxic to cells, therefore the mammary epithelial cells have to find a
way to transport large amounts of calcium to extracellular fluid, through their cytoplasm
into the milk.15 The large amount of calcium that leaves the mother results in mobilization
of skeletal calcium and a reduction in bone mass.15,16 Throughout this whole process,
calcium is transported through the milk ducts of the breast.

2.2 Calcification of the Breast
Calcium is one of the most important minerals in our body and it needs to be tightly
regulated. Calcium is found in the blood, muscles, and other tissues. It is essential for the
growth of strong teeth and bones, for heart function, blood clotting, nerves, and many other
functions in the human body. Calcium is also found in the dense tissue of the breast. This
5

mineral circulates in blood serum which is part of the blood plasma that does not contain
blood cells. Serum calcium is mostly controlled by calcium itself through different calcium
receptors and the two hormones: parathyroid hormone (PTH) and 1,25(OH)2 vitamin D.17
As PTH increases with age, its overproduction is suspected to be a risk for breast cancer.18
In a research conducted to study if calcium in blood serum is a risk factor for breast cancer
in women at pre/post menopause, it was found that a single measurement of serum calcium
is a useful marker for the difference in calcium homeostasis.19 In this same study, it was
found that calcium levels are positively associated with breast cancer in overweight peri/post menopausal women unlike women in their premenopause.19 As a result of the
hormonal change that occur, the misregulation of calcium level in breast tissue typically
seen after menopause is suspected to result in calcification.
Calcifications are results of small calcium deposits that develop in the breast tissue,
which commonly happens after menopause due to hormonal changes with an increase in
age.19 The calcification clusters are not necessarily related to the calcium from our diets
either. Calcifications have been proposed to be the result of the deposition of calcium
oxalate and/or calcium phosphate in the breast; however, the mechanism of the deposition
is not clearly understood yet.20 Calcium oxalate is produced by apocrine cells in the breast
and is mainly related to benign cystic change. Excess exposure to calcium oxalate could
affect the epithelial cells by triggering cellular and genetic changes, which promotes the
transformation of breast cells from normal to tumor cells.20,21 Although the exact
mechanism of calcification is not known, there are two scientific hypotheses: 1) calcium
secretion by glandular cells and 2) inability to clear regions during cell death. Sometimes
the granular cells of the breast can also release calcium into ducts, as the primary job of
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cells in that area is the secretion of milk. These calcifications then appear in the ducal
system, the breast acini, stroma, and vessels, mainly as calcium oxalate and calcium
phosphate. The second scientific hypothesis states the potential for the formation of
calcification from the deposition of dead cells in the breast tissue microenvironment. The
growth of unchecked cells crowding an area causes cell death but, if the body does not
flush dead cells out, they accumulate with a potential to form calcium deposits.22
Calcifications formed this way harden the breast tissue by converting into carbonates or
some other insoluble calcium components. In most instances, these calcifications are
benign (noncancerous), but certain types of calcification clusters could be indicators of
underlying breast cancer development. These two hypotheses do not necessarily work
synergistically instead it is either one or the other hypothesis that promotes the growth of
tumor cells. However, regardless of the mechanism of calcification clusters formation in
breast tissue, we need to have a technique to identify and ideally differentiate the types of
calcifications based on the type of calcium deposits (mainly tiny calcium deposits).
There are various patterns of calcification that occur in the breast which helps in
differentiating benign and malignant conditions. Calcifications could be larger or smaller
in size, therefore, a knowledge of calcification patterns during breast image analysis is
critical to distinguish benign from malignant. One way to differentiate calcifications is to
assess their morphology, size, appearance, and distribution in the breast. There are two
types of calcifications in breast tissue: microcalcification (MCs) and macrocalcification.
Macrocalcifications are defined as large typically >2 mm calcium deposits in the breast
tissue that are typically associated with benign, such as fat necrosis.20 They have a defined
shape (i.e Euclidean objects) that is mostly distributed or scattered randomly in a large
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volume (>2 cm3) throughout the breast microenvironment which often involves most of
the area in the breast. Macrocalcifications are large and mostly well-defined calcifications
that often appear as a line or as a dot in the mammogram. The different patterns of
macrocalcifications are seen and/or associated with the different parts of the breast. For
example, thin, round, and rim-like shape (Figure 2A) are often seen in the walls of cysts
(fat necrosis), coarse and popcorn-like shapes (Figure 2B) are often seen in degenerative
fibroadenomas, singe or parallel linear railroad patterns (Figure 2C) are often referred to
as vascular calcification, large and rod-like deposits (Figure 2D) often follow the ducts
toward the nipple, small rounded soft-tissue shadow looking (Figure 2E) often are milk
calcium, and round lucent-centered deposits (Figure 2F) often represent dermal
calcification.23

Figure 2: Macrocalcifications detected in a mammogram. A. rim or egg-shell type
calcification. B. degenerating fibroadenomas with coarse (A) and popcorn (B) calcification
C. linear, railroad track vascular calcification. D. thick, large, rod-like calcific foci. E. softtissue shadow of calcium with layering. F. a lucent-centered focus of dermal calcification.
G large, lucent-centered oil cyst. H. Intermediate concern amorphous calcification clusters.
Adopted from Ref. [20]
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On the other hand MCs are defined as smaller typically < 0.5 mm calcium deposits
in the breast tissue associated with malignancy such as ductal carcinoma in situ or invasive
carcinoma.23 The same study that was conducted to evaluate calcifications indicated that
patterns with fine, linear, segmental, branching or casting (Figure 3A) and pleomorphic
calcifications (Figure 3B) (calcifications of varying shapes and size) are often associated
with microcalcifications.23 This project is based on the analysis of MC clusters in
mammograms to differentiate them us benign and malignant clusters.

Figure 3: Microcalcifications typically associated with malignancy shown in
mammograms. A. fine, linear, branching calcifications. B. pleomorphic calcifications
(ductal carcinoma).
Adopted from Ref. [20]
The appearance and or the distribution of these two different calcification clusters
in mammography is one way to explain the state of the breast. If the calcifications are
grouped or clustered loosely (i.e <10/cm2) they are associated with a benign condition but,
if the calcifications are clustered in compact cluster (i.e >20/cm2) they are associated with
a malignant condition.24 A research that studied the average size of MC clusters in an area
in order to differentiate clustering of MC in mammograms for benign and malignant cases
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found that the mean number of microcalcifications per 0.25 cm2 was 16.4 in malignant and
16.7 in benign.24 The result from this study showed no statistical significance to
differentiate MC clusters in benign and malignant cases by looking at their average size
per a defined area in mammograms. Although the above and other studies in breast cancer
calcification differentiation have revealed the distribution, clustering, and pattern of
calcification clusters, microcalcification identification in breast image analysis could be
easy to miss. Additional factors that make the interpretation challenging is that some
deodorant or lotions applied on the skin appear in patterns that mimic calcification clusters
when images through mammography.
Radiographic microcalcification was first described in 1913 by Albert Salmon, a
surgeon in Berlin, who imaged over 3,000 surgical specimens describing the association of
microcalcifications with breast cancer and specimens that demonstrated tumors spreading
to the lymph nodes.2 To conclude this introductory exposition about microcalcifications,
MCs are smaller in size (compared to macrocalcifications) and oftentimes they appear as
clusters or randomly dispersed in the breast tissue. The detection and classification of
calcification clusters (in particular MCs) in a breast image is very important for early
detection of breast cancer. The early detection of cancer is very important to provide
patients with the necessary therapies or other treatments, or advice in maintaining dietary
health. In general, the development of a computational model that adds assistantship for
the radiological interpretation of breast images will help in minimizing the number of
women who suffer from treatments e.g, chemotherapy and save those who would have died
of the disease.
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CHAPTER 3: EPIDEMIOLOGY
Breast cancer is a very common worldwide disease affecting the lives of many
women with an increasing rate worldwide. It is the most frequent cancer among women
and holds the second places in cancer related death. A report by the World health
organization showed that about 2.1 million women get infected each year.25 About 1.67
million new cases were diagnosed in 2012 and in 2018 the estimated number of women
died from breast cancer is about 627,000.25,26 According to the World Bank classification
strategy, there are three major categories in health care investment, based on the gross
national income of the country. These three major categories are: Low Income Countries
(LICs), Low Middle Income Countries (LMICs), and High Income Countries (HICs). LICs
and LMICs are mostly classified as developing countries, and countries with HICs are
classified as developed countries. When looking at a country's annual income level, the
terminologies "developing" and "developed" are not necessarily used to define the
development status of a country; rather, they refer to the ability of the country to provide
adequate health care. In addition, this classification provides insight to how much the
country invests in providing the most relevant health care. Health care in developing
countries to provide breast screening for an early stage cancer detection might not be easily
accessible, unlike in developed countries. Because of the inability to provide reliable breast
screening, along with many other difficulties in getting the proper treatments, breast cancer
has a higher mortality rate in developing countries when compared with developed
countries. This is despite the fact that people in developed countries are affected at a higher
rate than developing countries. Breast cancer leads to approximately 500,000 cancer deaths
among women annually.26 The highest incidents occur in the most developed regions of
11

the world, with 74.1 new cases per 100,000 women, in comparison to the 1.3 new cases
per 100,000 observed in less-developed regions.26
Data collection in developing countries is very challenging, as it is extremely
scarce; however, studies have shown that the survival rate for cancer in developing
countries (LICs and MLICs) is lower than developed countries (HICs). Observing a 5-year
survival rate in female populations, a study found that in HICs countries like China,
Singapore, South Korea, and Turkey the median relative survival rate of breast cancer were
76-82%, whereas in LCIs countries like Gambia, the survival rate was 22%, and Uganda
was 46%.26,27 These survival rate values indicate the level of development in the health
care of the country to provide the necessary early diagnosis, treatment, and follow-up
clinicals for all patients. In developed countries there is better health care service and there
are many accessible advanced technologies that are used to treat patients with a relatively
affordable price. However, in developing countries the level of development of the health
care is relatively low with a very limited access to advanced medical technology for early
diagnosis, treatment, and clinical follow-ups. In addition, people who live in developing
countries have lower income with little to no affordable life insurance to help cover the
price of health care costs.
3.1 Breast Cancer in Developing Countries
Breast cancer has a higher effect on families in developing countries than in
developed countries in every aspect. Women in developing countries have more
responsibilities in their family setting and within the society than women in developed
countries. Any consequences that come with breast cancer like financial burden and the
need for time to take care of themselves are real challenges that these women face as they
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work restlessly to fulfil their responsibility. In addition, most of these women do not have
as much access to advanced health care services for early diagnosis of breast cancer. Breast
cancer is a rising world problem mostly in developing countries with studies as of 2002
showing it holds the fourth place in its effect on both sexes (men and women). Due to this
huge health care problem in developing countries, the disease is more aggressive in killing
many women which increases the mortality rate of that country per year. The shortage in
availability of health insurance companies to help cover the cost needed to get the diagnosis
and treatment of breast cancer is one other factor for the rise in death rate from breast
cancer. Most of the time health care providers like big hospitals are found in urban areas
rather than the rural areas and so women who live in the countryside do not have as much
opportunity to visit specialized doctors. Along with this, the literacy rate of women in the
countryside is lower than women in the urban areas which makes a difference in the
understanding of the effect of breast cancer and the initiation to seek help. Women in
underprivileged areas of Africa and Asian countries are unaware of the importance of
breast cancer screening and the necessary treatments needed after the diagnosis. All of
these predominant risk factors increase the number of women being affected by the disease
increasing the mortality rate which also affects the economy of the country.
A study conducted in North-Africa has shown that breast cancer is the most
common cancer among women representing 25% to 35% of cancer types that affect
female.28 The major risk factors in these areas include: family history, age at menopause,
age at menarche, breastfeeding, number of children, age at first child, oral contraceptives,
hormone replacement therapy, alcohol, and body mass index.29 Patients with a family
background of breast and/or ovarian cancer have a risk of getting breast cancer either from
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first, second, or third-degree relatives. In this same study, it was reported that
approximately among the 30% of patients that were diagnosed for breast cancer, it was
found that 7-9% of them had breast cancer in their family history.29 Menopause is defined
as the cessation of menses and the termination of ovarian follicular maturation due to loss
of the ability of the ovary to produce estrogen in significant quantities. The hormonal
changes during this period in some women could be a cause for health consequences like
breast cancer. Some of the reasons include: the increase in calcium retention in the kidney,
calcium reabsorption from the skeleton, and calcium reabsorption from the intestine before
and after menopause. The mean duration of breastfeeding time is significantly associated
with a reduced risk of breast cancer. Women whose lifetime breastfeeding duration is more
than 73 month has a lower risk of breast cancer.29 Studies have also shown that a longer
duration of breastfeeding time along with menopause status reduces the risk factor of breast
cancer. Overall, this analysis done on women in North African countries indicate
breastfeeding reduces the incidence of breast cancer by 4.3% for every 12 months and
incidence increase by 3% for every year menopause is delayed. Other risk factors that are
associated with breast cancer incidence include 16% reduced risk for every two births, 40%
increment for first birth after age 35 versus age before 20, 7% reduction for each year
menarche is delayed, and 32% increment for an intake of 35-44 g alcohol/day.29–31 Even
though these statistical values represent North African women, these risk factors are
common problems of most developing countries, especially in African countries.
Women in developing countries do not visit a doctor on a regular basis unlike most
females in developed countries. The main reasons for this are the limited access to hospitals
to go for screening and the available doctors to diagnose patients. Most of the time patients
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also do not visit doctors until cancer reaches the latest stage; even if the patient gets the
opportunity for early cancer stage breast screening, the patients do not seek treatment. This
delay in diagnosis facilitates the progress of the disease and the delay of getting the
necessary treatment minimizes the chance of survival. Due to this reason in many
developing countries, breast cancer is a slowly rising disease with high case-fatality rates
leading to the death of many adult women. This high case fatality rate is approximated by
the ratio of the mortality to the income across the developing world which further reflects
the inequities in early detection and access to treatment.32 According to the most recent
Globocan/IARC data the number of deaths as a percentage of incidence cases in 2008 was
48% in LICs and 40% in LMICs.33
Digital mammography and other advanced technologies for breast cancer diagnosis
are complicated and expensive resources. Screening and treatments are not readily
available for all women, therefore, the easiest way to address the problem is by creating
awareness. Educating women to live a healthy life, minimizing alcohol, exercising,
maintaining a healthy ideal body weight, and avoidance of postmenopausal hormone
replacement therapy can have a significant impact in reducing the probability of getting
breast cancer. According to World Health Organization, implementing these knowledge
into action could prevent up to one-third of new cancers and survival for another one-third
of cancers detected at an early stage.34 However, in addition to all these precautions to
prevent breast cancer and while many of the developing countries still battle for advanced
medical technology there is a high need for affordable and accessible healthcare for early
physical examination. The combination of education and effective healthcare service by
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trained medical personnel with the assistance of easily applicable technology has the
potential to enhance the fight against breast cancer.
3.2 Breast Cancer in Developed Countries
Breast cancer in HICs, developed countries, is much more controlled than in LICs
and LMICs, developing countries. Majority of the women in developed countries have easy
access to using adequate healthcare for an early breast cancer diagnosis and getting the
necessary treatment to prevent the cancer from growing to an advanced stage. In HICs one
of the greatest options that are readily available for women both in urban and rural areas is
the presence of health insurance companies that can assist individuals and families
financially. In addition, women in these countries are also educated better than women in
developing countries which plays a huge role in fighting against the disease.
Digital mammography screening in developed countries is the most common way
for early detection of breast cancer and it is highly associated with the reduced mortality
rate of cancer in developed nations. According to the International Agency for Research
on Cancer (IARC), there is sufficient evidence to show the reduction in the effective rate
of breast cancer among screened women of age between 50-74.35,36 Women in this age
range have indicated that the mammographic screening has reduced their risk of dying from
breast cancer by 23%. In general, those women who attended the screening program that
IARC has organized for this case-controlled study had about 40% reduction in the risk of
breast cancer.36 However, one of the problems with that could be associated with
mammographic screening for early breast cancer detection is the high probability for false
diagnosis resulting from potential misinterpretation of breast mammograms.
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CHAPTER 4: EXISTING SOLUTIONS
Cancer has been in medical history since as early as 1600 BC in the Edwin Smith
papyrus, where the oldest description of the illness existed.37 In the 2nd century AD, Aleius
Galenus (mostly referred as Galen), an ancient Greek physician and surgeon, made a
detailed categorization of abnormal growths (tumors), which he had seen occurring more
often in the breasts of women whose menstruation was either abnormal or inexistent.37
However, he had also suggested that cancer would better be treated at its early stage,
otherwise surgery would be a better solution for late stage cancer. Leonides of Alexandria
near the 2nd century AD distinguished between the scirrhous ( a hard cancerous growth
usually arising from connective tissue) and cancer in the breast, suggested the amputation
of the breast for any late stage cancer.37 Both of these two ancient physicians and other
ancient physicians, as well as modern doctors, explained that surgical treatments for cancer
past the early stage is an effective way of treating the disease.
4.1 Modern Breast Cancer Diagnosis
The most common technique that is being used to diagnose breast cancer in modern
times is breast screening. In 1975, about 45 years ago, a controlled trial of about 31,000
women age 40-64 were selected for a population study to determine the effectiveness of
breast cancer screening with mammography and clinical examination.38 Results from this
study showed that screening had led to a 30% reduction in cancer mortality rate.38 Since
1977, breast screenings for women above age 40 has been recommended for early detection
of cancer. However, guidelines for a proper screening were not yet well established until
1997. Then in 2002, the United States Preventive Service Task Force recommended
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screening mammograms every two years then in 2016 they recommended getting breast
cancer screening every year for women of age between 50-74.39
4.1.1 Current Imaging Techniques
The use of screening techniques to diagnose abnormalities in breast cancer has
evolved rapidly in the 20th century with mammography having been fully developed in the
1960s.40 The history of mammography is divided into three phases; the foundation of
mammography was laid in 1913 by the observation that a German surgeon made, from
1940 - 1970 followed the development of mammography by different radiologists and
industry, and the last phase started close to the end of the 20th century where breast cancer
screening started.38 At the last quarter of the 20th century, most of the modern techniques
like ultrasound, magnetic resonance imaging (MRI), and digital mammography started to
be used for breast cancer screening.41 The third phase of the development is when most
women started to be screened for breast cancer. The quality of mammography has
improved since 1950s where Greshon Cohen and his associates have identified benign and
malignant abnormalities, and further reported on the potential of mammography as
diagnosing tool.42 A report posted in 1973 on the results of the Health Insurance Plan of
Greater New York randomized, controlled, breast cancer screening study showed that
women who got breast screening 5 years before the report was made has showed a one
third reduction in breast cancer mortality rate.42 In the late 70s, sonography, a medical
diagnostic method using high-frequency sound waves like ultrasound to create an image
of the breast, was developed, which complemented mammography.41,43 Nevertheless, this
technique was not efficient enough to replace mammography fully as it lacks the ability to
detect the presence of microcalcifications, which are a major indicator for the formation of
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breast cancer. By the end of the 80s, MRI became a more important diagnostic tool, but it
was not efficient enough to detect the presence of microcalcifications and it was too
expensive to be used by every health care center.43 Even though mammography has been
recognized as a medical diagnostic technique for breast cancer screening, there is still a
need to improve the CAD system to improve mammogram analysis for a better patient
care.
Mammography. There are two different kinds of mammography: digital
mammography and film mammography. Digital mammography refers to the application of
digital system, techniques, on mammography, which are created when a conventional
mammography is digitized to be used in computers.44 Film mammography refers to a
system where breast images taken using conventional mammography are read and stored
on film. The use of conventional breast screenings by radiologists has created problems of
increased probability of false diagnoses or negative readings, which decrease the chance
for early detection of abnormalities in breast tissue.41 As a greater density of breast tissue
reduces the sensitivity of mammography, digital mammography is made to improve film
mammography, as it separates and optimizes image acquisition and display.41 According
to a research study that was conducted to test which of the two mammography techniques
would better analyze breast cancer in young women, premenopausal and perimenopausal
women, and women with dense breasts, it was understood that digital mammography is
more efficient than film mammography.41 There is no significant difference between these
two techniques, however, digital mammography offers easy access to images, can easily
work with CAD, and uses a lower average dose of radiation without a compromise in
diagnostic accuracy. In digital mammography, X-ray transmission could be manipulated

19

to adjust image contrast, which enhances the visualization of problematic areas (areas
where mass or clusters of calcifications are present) like adjacent dense tissue where the
cancer tumor could probably hide without altering its accuracy in diagnosis.41
Mammographic images are taken from different angles, but the major views that
radiologists look into are the cranial-caudal (CC view) and mediolateral oblique (MLO).
In the CC view, the entire breast is depicted as the breast is flattened out in between two
plates at exactly 180o and/or 0o, whereas in the MLO view, the breast image is taken from
a 90o projection as shown in Figure 4.45 Both of these views together must show the medial
part as well as the external lateral portion of the breast. The CC projection may show the
pectoral muscle on the posterior edge of the breast, indicating that the breast is positioned
as forward as it could go.46 The MLO projection is a very important view as more of the
breast tissue are captured in the image and the lateral side of the breast is predicted to be
the most common place for pathological changes.46 In MLO view, the amount of pectoral
muscle that is showing in mammograms is an indicator for the amount of breast tissue that
is included in the image.

Figure 4: The CC (180o and/or 0o projection) and MLO (90o projection ) views of
mammographic breast image. Adopted from Ref.[45]
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Magnetic Resonance Imaging (MRI). Breast magnetic resonance imaging (MRI) has a very
high sensitivity degree in detecting breast cancer, regardless of the breast tissue. MRI is
very useful, especially for those women who are at a higher risk of getting breast cancer,
which includes women with genetic predisposition and women with a family history of
ovarian and/or breast cancer.47 Breast MRI has the potential to detect abnormalities in
breast tissue better than physical examination, mammography and ultrasound. But MRI is
not effective in identifying microcalcifications inside the breast tissue. MRI is effective in
identifying some occult tumors in a very dense breast tissue, for which mammography
usually has difficulty in identifying the size and shape of abnormal spots.48
The use of MRI has shown a greater impact on the diagnosis of breast cancer,
however, distinguishing fat from a critical tissue lesion is a challenge in breast MRI. In a
study that was held to assess the effectiveness of MRI, it was found that breast MRI has
identified suspicious lesions in 76% of stage II patients and 86% of stage IV patients.48 As
tissue lesions could be a potential area for malignant cancer growth, it is very important
that they are identified and distinguished in any breast image. One of the challenges in
breast MRI is that there are a group of women in a small percentage whose normal
glandular tissue exhibits intermediate to strong early phase enhancement after contrast
administration, which could result in false positive diagnosis.47 Nevertheless, breast MRI
cannot be used as the only means to diagnose breast cancer for early stage detection.
Rather, it is more effective when it is used in alternation with mammography.
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4.2 Challenges with Existing Solutions
Breast cancer is easily detected using different imaging techniques in which the
presence of irregularly or abnormally shaped structures are detected to characterize and
discriminate between cancerous and non-cancerous tissue. Despite its usefulness, medical
imaging is a challenging task and it requires input from different trained people and digital
aid from technologies. Digital mammography has been in application for a long period of
time, helping to minimize the breast cancer mortality rate. Since CAD techniques have
been introduced to the medical field, particularly to digital mammograms, they have
assisted radiologists by providing a useful computerized vision. However, CAD usage has
been associated with increased false diagnostics and unnecessary biopsies, which lead to
stress to the patient and a financial burden to the healthcare system.49–56
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CHAPTER 5: APPLICATION OF FRACTAL GEOMETRY IN BREAST CANCER
DIAGNOSIS

Fractal geometry studies non-Euclidean objects or objects with an irregular shape
whose dimensions are statistical quantities indicating how irregular the object is rather than
a commonly defined integer dimension. Fractals by nature repeat themselves as the bigger
object is zoomed into finer pieces, exhibiting details at every size scale. These objects exist
in nature, biology, medicine, and everywhere. Euclidean geometry is used to describe
objects that have a smooth shape: lines, circles, cubes, etc. However, fractals do not possess
the characteristics of the so-called Euclidean geometry. One of the major differences that
B. Mandelbort (father of fractal geometry) has identified when he first introduced fractal
geometry is self-similarity. One of the simplest objects to illustrate this concept of selfsimilarity in fractals is Sierpinski’s triangle (Figure 5). All the smaller triangle pieces are
similar to the full-size set. In nature, however, such self-similarity is not exact like
Sierpinski’s triangle, but rather, the self-similarity is statistical.

Figure 5: Sierpinski’s triangle
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The fractal dimension is a tool used to describe fractal objects quantitatively in
order to characterize how much space they occupy. The non-integer fractal dimension of
fractals sits in between the Euclidean, integer dimensions. One way to estimate the fractal
dimension for 2D objects is by using the box counting method. This method accounts for
the power-law relation between the number of boxes of various sizes that are required to
cover the fractal set and the radius of each box to calculate the fractal dimension:
D = log N(r) / log (1/r)

Eq. 1

where N(r) is the number of boxes of radius r needed to cover the space, and D is the fractal
dimension obtained from the slope of the log-log plot of N and 1/r. However, the boxcounting method is not easily applicable in image analysis. For example, an image of the
breast taken by digital mammography may have a multifractal nature but since the box
counting method is limited in its applications it cannot be used to study the fractality of
breast tumor. Therefore, a more powerful method is a requirement to improve early cancer
detection. In this project the fractal dimension of breast tumors (MC clusters) calculated
from the analysis of mammograms with the aid of the 2D WTMM (further discussed in
section 5.1) is explored.
Another area where the analysis of images with multifractal nature plays part is in
its use to study the architecture of breast microenvironment surrounding tumors. As
described in Chapter 2, MC clusters have different forms of morphology and irregularity
in their architecture inside the breast tissue which radiologists have mostly been using
qualitative ways of describing malignancy and tissue lesion. Previous researchers have
studied the use of fractal characteristics in ultrasound images to analyze microcalcifications
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and differentiate tissue lesions to distinguish benign from malignant.44 The most frequently
used technique in analyzing digital mammography images using fractals is to use a fractalbased segmentation technique to analyze the self-similar nature in microcalcification
clusters.47 This way of analyzing mammograms provides a better insight to tissue
architecture and disruption with the ability to quantitatively assess tumor cell growth. In
general, the use of techniques like this for the analysis of complex images like
mammograms has shown a promising methodology in understanding the state of tissue
homeostasis of the microenvironment surrounding the MC clusters.
One way to analyze mammograms to investigate the microenvironment
surrounding tumors is to study image density fluctuations, i.e. surface roughness, as
quantified by an exponent such as the Hurst exponent. Several techniques can be used to
estimate such roughness exponents, including the autocorrelation function, the root-meansquare analysis, the Fourier power spectral analysis, and the 2D WTMM method (for
example, see Ref [57]). Even though the H values that are used later in this thesis were
obtained from the 2D WTMM method, for simplicity, a brief overview of the Fourier
power spectral analysis follows.
A Fourier power spectral analysis consists in studying the power-law relationship
between the Fourier spectral power vs. spatial frequency. In statistics, the power-law states
that a relative change in one quantity results in a proportional relative change in another.
Fractal functions are functions that show the representation of multiple frequencies at play
where there is not necessarily one dominating frequency (represented as one peak in the
power distribution), but rather, a power-law distribution of spectral power spectrum vs. the
spatial frequencies. These functions behave like a power-law.
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S(k) ~ (1/k)β

Eq. 2

where S(k) is the power spectrum, k represents the spatial frequency, and β is the power
spectral exponent, which is related to the Hurst exponent, H, quantifying roughness.
β = 2H - 2

Eq. 3

As mentioned above, this concept of quantifying roughness using the Hurst exponent has
been applied in different studies, the Hurst exponent values used for this project are not
obtained by the power spectral analysis instead they are results from the 2D WTMM
analysis method.7
5.1 The 2D Wavelet Transform Modulus Maxima Method
The Wavelet Transform Modulus Maxima (WTMM) method is a multifractal
formalism used to analyze complex 1D signals, 2D images, 3D images, and vector fields.58
Wavelets are rapidly oscillating signals that are useful in analyzing the singularity of
fractals and the WTMM can be used to estimate the strength of these singularities in a
signal. Singularity in mathematics refers to the non-defined shape or irregular regions of
an image that lacks differentiability or analyzability as compared to defined shapes.
Therefore, the WTMM method is a way of performing multifractal analysis in a
multifractal formalism using wavelets instead of boxes. The WTMM were first explored
by Mallat and Hwang in 1992 for signal processing purposes to compute the singularities
of 1D functions.59 Then A. Arneodo developed the WTMM method as a multifractal
method, first in 1D,58,60 and then in 2D, 3D, and for vector fields.61,62
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The wavelet transform (WT) is a mathematical microscope that is capable of
analyzing complex non-stationary time series.61,62 The continuous WT characterizes spatial
image information over a continuous range of size scales. The increase in magnification in
this singularity scanner can reveal and quantify details of a signal irregularity using the
Holder exponent, h.63 A previous study conducted in 2014 by CompuMAINE lab has
shown that the 2D WTMM method is promising to be used in studying the architecture of
breast tissue lesion. In the study, multifractal analysis of mammograms was performed,
where the Holder exponent, h, characterizing the strength of singularity was used to
differentiate the MC from the background tissue. MCs were segregated from the
background tissue by considering two pieces of information: the strength of the modulus
of the WT at the smallest scale and the variation of the slope, h, across the scales.
The breast in Figure 6 shows the 2D WTMM analysis of a dense tissue whose
roughness fluctuation is characterized by a relatively high smoothness level. The image in
Figure 6A and 6B show the mammogram of a dense breast and suspicious region
containing MC clusters circled by a radiologist respectively. The images from Figure 6C
to 6G shows the 2D WTMM analysis of the circled region segmenting the MC (red) from
the background tissue (blue). After the segmentation was done, the fractal dimension, D,
of the lesion was calculated. As the histograms in Figure 7 demonstrate, the outcome of
this study reveals that benign lesions have fractal dimensions with a strong preference for
Euclidean dimensions, either to the far right (=2) or to the far left (=1), whereas malignant
lesions have fractal dimension with a strong preference for the middle of the curve with a
value between 1<D<2.
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Figure 6: Sample 2D WTMM analysis of a malignant breast lesion. A. mammogram of a
dense breast tissue. B. suspected area of microcalcifications circled by a radiologist. C-G
the 2D WTMM analysis of the circled region to differentiate between MC clusters (red)
and the background tissue (blue) surrounding them. Adopted from Ref.[7]

Figure 7: Histogram plot of the fractal dimension, D for both benign and malignant in both
mammographic views. Adopted from Ref. [7]
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The histograms in Figure 7 indicate the preference in (non-integer) fractal
dimension for malignant vs. Euclidean dimension for benign in both CC and MLO views
separately. The 2D CC-MLO fractal dimension plot in Figure 8 is an additional evidence
that shows the difference between malignant and benign cases. In this plot the x-axis
corresponds to the fractal dimension values for both benign (green) and malignant (red)
MC clusters from the CC view and the y-axis corresponds to the fractal dimension values
for both benign and malignant MC clusters from the MLO view. The identified polygonal
region in Figure 8 shows that benign cases prefer the region outside the polygon which is
identified to be the Euclidean zone and the malignant cases prefer the region inside the
polygon which is identified to be the fractal zone.7

Figure 8: The CC-MLO fractal dimension plot is a graph of all the benign and malignant
cases fractal dimensions from the MLO view as a function of fractal dimension from the
CC view. The red dots represent malignant cases and green dots represent benign cases.
Inside of the polygon is defined as the fractal zone and outside of the polygon is defined as
the Euclidean zone. Adopted from Ref. [7]
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This same research team conducted another research in 2017 using the 2D WTMM
method aiming to show that tissue disruption and loss of homeostasis in breast tissue
microenvironment, and breast bilateral asymmetry can be quantitatively and objectively
characterized by assessing mammograms. The density fluctuation in the microenvironment
of the breast due to tissue disruption was quantified by using the Hurst exponent, H. The
Hurst exponent, H is a quantifier of the global roughness of an image density fluctuation
which was first introduced to the 2D WTMM analysis of mammogram by Kestener et al.64
This is a potential tool to discriminate dense and fatty breast tissue as dense tissues are
mostly described as risk areas of breast cancer. The density fluctuations in healthy breast
tissue are either monofractal anti-correlated with H<½ for fatty tissue or monofractal longrange correlated with H>½ for dense tissue.
The outcome of Kestener’s study has shown that fatty areas have H - 0.30 whereas
dense areas have H values ~0.65. But although promising, Kestener’s study was based only
on a handful of mammograms. In a seminal paper published in 2017, the CompuMAINE
Lab improved the approach, scaled it up to hundreds of mammograms, and made an
important discovery, which has led to the recent award of a patent.65 After the calculation
of H values was done a sliding window technique using the 2D WTMM method was used
to determine the parameters that are most effective in distinguishing between normal and
tumorous cases. The results demonstrated that disrupted regions associated with loss of
tissue homeostasis are quantified by H~½.11 The values for H were associated with colors,
as shown in Figure 9 yellow for 0.45<H<0.55 (disrupted tissue region), blue for H<= 0.45
(fatty tissue) and red for H>=0.55 (dense tissue).13 In general, in this study the team was
able to develop the “yellow square analysis” based on H signature for different regions in
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the breast microenvironment which has moved the process of studying the correlation
between tissue disruption with loss of tissue homeostasis one step forward.

FATTY TISSUE
H<0.45
DISRUPTED
TISSUE
0.45<H<0.55
DENSE TISSUE
H>0.55
Opposite breast

Cancerous breast

Figure 9: Sliding-window analysis of a cancer case showing more disrupted (yellow)
tissue in the cancerous breast than the opposite breast. Each pixel represents a 360 x 360pixel mammogram sub-region colored according to its H value. Taken from Ref. [11]

5.2 Analysis and Discussion
This project consists in revisiting existing data from the CompuMAINE Lab, where
a wavelet-based technique was developed and launched on a dataset of mammograms with
MC clusters. The mammograms for data analysis were taken from an online data bank
called the Digital Database for Screening Mammography (DDSM). They are the same sets
of mammograms that were used in the CompuMAINE Lab’s 2014 study.7 The obtained
mammograms included both the MLO and the CC view of 33 benign cases and 25
malignant cases. The images were analyzed using the 2D WTMM method where the fractal
dimension for the MC were already calculated and published in 2014. Also calculated at
the time, but not included in the 2014 paper were the Hurst exponents for the background
microenvironment tissue surrounding the MC’s (based on the blue curves shown in Figure
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6 C, D, and F)7. For this project the values for the fractal dimension were collected in order
to study its correlation with Hurst exponent, H.
The values for both fractal dimension, D, for the MC clusters and Hurst exponent,
H, for the background tissue were obtained from the 2014 study’s results spreadsheet for
further analysis. A separate excel spreadsheet was prepared with columns containing just
values of D and H, for both MLO and CC views. We then graphed the fractal dimension,
D, as a function of the Hurst exponent, H. R66 was used to plot two separate “2D Hurst
exponent vs fractal dimension” graphs for CC and MLO views, as shown in Figures 10a
and 10b, respectively. The behavior of the data points for both benign and malignant cases
was then studied to identify a region that best represents the relationship between the Hurst
exponent and the fractal dimension in distinguishing between the two cases (benign and
malignant) in both CC and MLO view. From this plot the quadrilateral region is identified
as a region of interest to show the difference between benign and malignant cases. The
quadrilateral region extends in the x-direction from Hurst value of 0.2 to 0.8 centered at
0.5 and it stretches vertically from fractal dimension value of 1.0 to 2.0 centered at 1.5. The
range for D value from 1.0 to 2.0 was selected considering that MC clusters have a fractal
dimension in between Euclidean dimension as shown in the histograms in Figure 7. The
Hurst exponent range from 0.2 to 0.8 was chosen considering that disrupted tissue regions
have Hurst between 0.45<H<0.55 and to further encompass both fatty and disrupted tissue
regions according to Figure 9. Based on a manual count 15 malignant cases out of 25 cases
(60% of all the cases) in CC view (Figure 10a), and 17 malignant cases out of 25 cases
(68% of all the cases) in MLO view (Figure 10b) are found to be inside the quadrilateral
region. However, only 7 benign cases out of 33 cases (21% of all the cases) in CC view
32

and only 4 benign cases out of 33 cases (12% of all the cases) in MLO view are found to
be inside the quadrilateral region. This difference in region preference shows that there is
a correlation between the Hurst value of the background tissue and the fractal dimension
value of MC clusters to differentiate benign cases from malignant cases.

Figure 10: Fractal dimension vs Hurst exponent shown for both CC (a) and MLO (b)
indicates the correlation between H and D in differentiating benign MC (green) from
malignant MC (red). The identified quadrilateral region is centered at [0.5,1.5] and it extends
horizontally between 0.2<H<0.8 and vertically between 1.0<D<2.0. The benign MC have a
preference to reside outside the quadrilateral region, whereas the malignant MC have a
preference to reside in the inside of the quadrilateral region.
In the 2014 paper the “2D CC-MLO fractal dimension plot”, as shown here in
Figure 8, was graphed to demonstrate the relationship between malignant and benign cases
when D from the MLO view is plotted as a function of D from the CC view. Following the
graphical analysis from Figure 10, we also graphed a 2D scatter plot just for the Hurst
exponent, H, obtained for both benign and malignant cases, where H from MLO view is
plotted as a function of CC view, as shown in Figure 11a. A box plot is then used to show
the distribution of benign and malignant cases in both CC view (Figure 11b) and MLO
view (Figure 11c). In the 2D scatter plot shown in Figure 10a, if we consider the central
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point (0.5,0.5), according to the box plots in Figure 11b and 11c, ~75% of the malignant
cases (red dots) are located near the (0.5,0.5) region with the median of H ~ 0.5. On the
other hand, again from the box plots analysis in Figure 11b and 11c, ~75% of the benign
cases (green dots) are located near the coordinate (0.36,0.36) with median of H ~ 0.36.
Then p-value was evaluated using the nonparametric Wilcoxon rank sum test for a
statistical comparison between the Hurst values of benign and malignant cases. The p-value
obtained for H(CC) is 0.00257 (<0.05) and p-value obtained for H(MLO) is 0.00544
(<0.05) which shows that there is a statistically significant difference between Hurst values
of benign and malignant cases. The observation of the Hurst exponent, H, scatter plot and
the box plot analysis in Figure 11, and the p-values for H, indicates that background breast
tissue microenvironment surrounding microcalcification has some disruption. This can also
be confirmed by the outcome from the 2017 study as the median value H ~ 0.5 is in the
range 0.45<H<0.55 which is identified to be disrupted tissue region.13
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Figure 11: The 2D scatter plot (a.) represents the Hurst value, H, from MLO view plotted
as a function of H from CC view for benign MC (green dots) and malignant MC (red dots).
The two box plots for CC view (b.) and MLO view (c.) show that malignant cases (red
box) have a strong preference of median near H = 0.5 unlike benign cases (green box).
We calculated a new variable denoted generally as, Z. This new variable represents
the distance calculated for each Hurst exponent, H, of benign and malignant cases from
two radial centers in the H(MLO) vs. H(CC) plot shown in Figure 9a: (0,0) and (0.5,0.5)
using the distance equation.
𝑍 = #((𝑥& − 𝑥( )( + (𝑦& − 𝑦( )( )
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Eq. 4

These two radial centers are chosen to analyze the behavior of both malignant and benign
cases between 0-0.5 as this range of Hurst is an indicator of anti-persistent (anticorrelation) behavior. The variables are calculated for CC and MLO views separately. The
Z calculated from the center point (0.5,0.5) is denoted as Z0.5, and the Z calculated from the
center point (0,0) is denoted as Z0.0. They represent how far away each data points for
benign and malignant cases are from each center points. The box plots shown in Figures
12A and 12B are used to statistically analyze differences between malignant and benign
cases for each variables Z0.0 and Z0.5 respectively. Then the p-value was evaluated using
the nonparametric Wilcoxon rank sum test in R to statistically compare the obtained values
of Z0.0 and Z0.5 for benign and malignant cases.

Figure 12: A box plot representing the statistical difference between Z0.5 (A) and Z0.0 (B)
for both benign cases (green box) and malignant cases (red box).
The box plot in Figure 12 compares the distance Z0.0 and Z0.5 calculated for both
benign (green box) and malignant cases (red box). The median of Z0.5, for benign cases is
0.1664 whereas the median for malignant cases is 0.2126. The median for Z0.0, for benign
cases is 0.5243 whereas the median for malignant cases is 0.7004. The median of benign
cases is greater than the median of malignant cases for Z0.5, however, the median for benign
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cases is less than the median of malignant cases for Z0.0. These median values show that
there exists a difference between the benign cases and malignant cases in terms of choosing
a region to reside. The p-value for Z0.5 is 0.1634 (>0.05) which shows that there is no
statistically significant difference between the distance of each data point from the center
for both benign and malignant cases. Whereas the p-value for Z0.0 is 0.001066 (<0.05)
which shows that there is a statistically significant difference between the distance of
benign and malignant cases from the center (0,0). These statistical results are indicators
such that when the 3D graph for D vs H is plotted, there is an expectation for more
malignant cases (red dots) to be near 0, the origin and more benign cases (green dots) to be
far away from the origin. In addition, the statistical analysis of the box plot in R showed
that 75% of the malignant cases have Z0.0 < 0.7844 and Z0.5 < 0.2599, and 75% of the
benign cases have Z0.0 < 0.5872 and Z0.5 < 0.3471. Based on these results, when the 3D
graph for Hurst exponent vs fractal dimension is plotted, one can expect to see relatively
more benign cases far away from the origin for Z0.5 and more malignant cases near the
origin for Z0.0. The closer the H values are to 0, the stronger is the tendency for the time
series to revert to its long term means value. This means that there is tissue disruption in
the microenvironment of breast surrounding malignant MC clusters. This analysis also
indicates the quantifiable relationship between the Hurst exponent quantifying tissue
disruption and fractal dimension of MC clusters in differentiating between benign and
malignant cases. However, there is a need for further analysis of this relationship with more
data to make a conclusion confirming the presence of tissue disruption in all malignant MC
clusters that could be applied for a reliable diagnostic process.
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Next, we wanted to combine the information on the x and y from the 2D CC-MLO
Hurst exponent plot with the 2D CC-MLO fractal dimension plot from 2014 (Figure 8).
Together this created 4-dimensional data information. However, since a 4-dimensional plot
is not possible to graph, we instead decided to consider the information in a 3D plot
combining D(CC), D(MLO), and Z as shown in Figure 13. To do so, we used the fractal
dimension D for CC to go in the x-axis, D from the MLO view to go in the y-axis, and the
variables Z0.0 and the Z0.5, respectively, to go in the z-axis. The two variables Z0.0 and Z0.5,
calculated above represent the combined Hurst exponent, H, from CC and MLO views for
benign and malignant cases. Two separate graphs one with Z0.0 in the z-axis and another
with Z0.5 in the z-axis but, with same D from CC and D from MLO was used to graph the
“3D CC-MLO fractal dimension vs Hurst exponent” plots, as shown in Figure 13. Although
there is not a clear pattern that the data points follow, the 3D plots in Figure 13
demonstrates the 4-dimensional information relating the Hurst exponent, H, and fractal
dimension, D, of benign and malignant cases from both CC and MLO views. No statistical
analyses were performed on these 3D data, but we qualitatively observed that there seem
to be a relationship between the Hurst exponent, H, quantifying the disruption in the
surrounding breast tissue and the fractal dimension, D, showing the fractality of the MC
clusters.
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Figure 13: 3D plot of D from CC (x-axis) and MLO (y-axis) against the variable Z0.0, (a),
and Z0.5 (b).
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CHAPTER 6: CONCLUSION

Microcalcifications inside the breast tissue sometimes grow into a cancerous tumor.
The identification, characterization and quantification of MC clusters when analyzing
mammograms is very useful for early cancer detection. In a previous study done by
CompuMAINE Lab in 2014, mammograms were analyzed with the aid of the 2D WTMM
method and it was found that malignant MC clusters have a fractal nature. The
microenvironment surrounding these MC clusters also plays a role in identification of
suspicious areas leading to possible cancerous tumor growth. A separate study done by this
same team in 2017 used the 2D WTMM method to analyze mammograms which showed
that the loss of tissue homeostasis in the breast microenvironment leading to tissue
disruption can be quantified by the global roughness exponent, H.13 The results from this
study has found that the Hurst value for a disrupted tissue region is between 0.45<H<0.55.
In this project the correlation between the Hurst exponent value for the background
tissue surrounding MC clusters and the fractal dimension of MC clusters was studied. In
the “2D fractal dimension vs. Hurst exponent plot” nearly 75% of the malignant cases are
found inside the quadrilateral region centered at the point (0.5,1.5). Since H ~ 0.5 is
associated with a disrupted tissue region and D ~ 1.5 is associated with malignant MC
clusters, we can conclude that there is a relationship between the state of the
microenvironment in cancerous breast tissue and microcalcifications clustering in that
region. The 3D graph in Figure 13 is an additional supporting evidence for this relationship.
As a conclusion, based on the outcomes of this study one can hypothesize that with further
analyses, loss of tissue homeostasis describing the state of the microenvironment of a breast
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tissue and the fractal nature of MC clusters have a quantifiable relationship to distinguish
benign cases from malignant cases in mammogram analysis. This outcome also leads to a
future work that can be employed to distinguish whether it is the tissue disruption as a
result of loss of tissue homeostasis that is facilitating the growth of microcalcification
clusters or vice-versa.
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